JPRN-jRCT2031210497招募中2 期
ate phase II study of NS-304 in patients with intermittent claudication (IC) resulting from arteriosclerosis obliterans (ASO)
Higashioka Masaya0 个研究点目标入组 200 人开始时间: 2021年12月17日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patients with intermittent claudication (IC) resulting from arteriosclerosis obliterans (ASO)
- •2.Patients whose ABI is not more than 0.90 at rest.
- •3.Patients whose mean PWT measured in the treadmill exercise test meets selection criteria.
排除标准
- •Patients who have severe ischemia of lower extremities of Stage III or over in Fontaine classification or potentially has severe ischemia of lower extremities
研究者
相似试验
已完成
2 期
ate phase II study of NS-304 in patients with intermittent claudication (IC) resulting from arteriosclerosis obliterans (ASO)Arteriosclerosis obliterans (ASO)JPRN-jRCT2080223273ippon Shinyaku Co., Ltd.342
未知
2 期
ONO-2745 Phase II StudyPatients undergoing a surgery under general anesthesia requiring opiate analgesticsJPRN-jRCT2080221456ONO PHARMACEUTICAL CO.,LTD.90
已完成
2 期
ate Phase II Study of TS-142 in Patients with InsomniaInsomnia DisorderJPRN-jRCT2080225269Taisho Pharmaceutical Co., Ltd.160
未知
1 期
Phase 1/2 study of NS-065/NCNP-01 in patients with Duchenne muscular dystrophyDuchenne muscular dystrophyJPRN-jRCT2080223236IPPON SHINYAKU CO., LTD.16
招募中
2 期
A Phase 2 clinical study to assess efficacy of Induction ipilimumab/nivolumab to spare the Bladder in urothelial bladder cancer (IndiBlade)Urothelial carcinoma of the bladder and bladder cancer10038364NL-OMON52087Antoni van Leeuwenhoek Ziekenhuis50